Validation of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Coding in <scp>US</scp> Claims Data
We found that a patient cohort identified using claims-based CIDP diagnoses included a substantial number of patients with other chronic inflammatory acquired neuropathies not formally recognized as CIDP by clinical consensus criteria. Requiring two CIDP codes can improve PPVs.
Authors
- Sebastian Schneeweiß (ORCID: https://orcid.org/0000-0003-2575-467X)
- Priyanka Anand (ORCID: https://orcid.org/0000-0002-0945-4100)
- Hakan Ay (ORCID: https://orcid.org/0000-0003-4638-0750)
- Zhigang Lu
- Kueiyu Joshua Lin (ORCID: https://orcid.org/0000-0003-4564-3715)
- Reza Sadjadi (ORCID: https://orcid.org/0000-0003-3829-6030)
- Colin Anderson‐Smits (ORCID: https://orcid.org/0000-0002-2734-6154)
- William Spalding (ORCID: https://orcid.org/0000-0002-2950-2931)
- Erika K. Williams
- Joshua U. Okonkwo
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Takeda (United States) (US)
- Mass General Brigham (US)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/pds.70123
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Takeda Pharmaceutical Company